Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Therapeutics (NASDAQ: ANIK) has announced the granting of non-statutory stock options to a newly hired non-executive employee on April 1, 2025. The options cover 3,800 shares of common stock with an exercise price of $15.03 per share, matching the closing price on Nasdaq Global Select Market on the grant date.
The options were granted under the Anika Therapeutics 2021 Inducement Plan and approved by the compensation committee. The vesting schedule includes one-third of the shares vesting on each of the first three anniversaries of the grant date, contingent on continuous service. The options will expire after ten years and were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Anika Therapeutics (NASDAQ: ANIK) ha annunciato il conferimento di opzioni su azioni non statutarie a un nuovo dipendente non esecutivo il 1 aprile 2025. Le opzioni coprono 3.800 azioni ordinarie con un prezzo di esercizio di $15,03 per azione, corrispondente al prezzo di chiusura sul Nasdaq Global Select Market alla data di concessione.
Le opzioni sono state concesse nell'ambito del Piano di Induzione 2021 di Anika Therapeutics e approvate dal comitato per la compensazione. Il piano di maturazione prevede che un terzo delle azioni maturi in ciascuno dei primi tre anniversari della data di concessione, a condizione che il servizio continui. Le opzioni scadranno dopo dieci anni e sono state concesse come un incentivo materiale all'impiego in conformità con la Regola 5635(c)(4) delle quotazioni Nasdaq.
Anika Therapeutics (NASDAQ: ANIK) ha anunciado la concesión de opciones sobre acciones no estatutarias a un nuevo empleado no ejecutivo el 1 de abril de 2025. Las opciones cubren 3,800 acciones ordinarias con un precio de ejercicio de $15.03 por acción, igualando el precio de cierre en el Nasdaq Global Select Market en la fecha de concesión.
Las opciones se otorgaron bajo el Plan de Inducción 2021 de Anika Therapeutics y fueron aprobadas por el comité de compensación. El calendario de adquisición incluye un tercio de las acciones que se adquirirán en cada uno de los tres primeros aniversarios de la fecha de concesión, condicionado a la continuidad del servicio. Las opciones expirarán después de diez años y se otorgaron como un incentivo material para el empleo de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
아니카 테라퓨틱스 (NASDAQ: ANIK)는 2025년 4월 1일에 새로 고용된 비상임 직원에게 비법정 주식 옵션을 부여했다고 발표했습니다. 이 옵션은 $15.03의 행사 가격으로 3,800주를 포함하며, 부여일의 나스닥 글로벌 셀렉트 마켓에서의 종가와 일치합니다.
이 옵션은 아니카 테라퓨틱스 2021 유도 계획에 따라 부여되었으며 보상 위원회의 승인을 받았습니다. 옵션의 베스팅 일정은 부여일의 첫 세 번째 기념일마다 1/3의 주식이 베스팅되며, 지속적인 서비스에 따라 달라집니다. 옵션은 10년 후에 만료되며, Nasdaq 상장 규칙 5635(c)(4)에 따라 고용에 대한 실질적인 유인으로 부여되었습니다.
Anika Therapeutics (NASDAQ: ANIK) a annoncé l'octroi d'options sur actions non statutaires à un nouvel employé non exécutif le 1er avril 2025. Les options couvrent 3 800 actions ordinaires avec un prix d'exercice de $15,03 par action, correspondant au prix de clôture sur le Nasdaq Global Select Market à la date d'octroi.
Les options ont été accordées dans le cadre du Plan d'Induction 2021 d'Anika Therapeutics et approuvées par le comité de rémunération. Le calendrier de vesting prévoit qu'un tiers des actions sera acquis à chacune des trois premières anniversaires de la date d'octroi, sous réserve d'un service continu. Les options expireront après dix ans et ont été accordées comme un incitatif matériel à l'emploi conformément à la Règle de Cotation 5635(c)(4) de Nasdaq.
Anika Therapeutics (NASDAQ: ANIK) hat die Gewährung von nicht-statutären Aktienoptionen an einen neu eingestellten nicht-executive Mitarbeiter am 1. April 2025 bekannt gegeben. Die Optionen beziehen sich auf 3.800 Stammaktien mit einem Ausübungspreis von $15,03 pro Aktie, was dem Schlusskurs am Nasdaq Global Select Market am Tag der Gewährung entspricht.
Die Optionen wurden im Rahmen des Anika Therapeutics 2021 Induktionsplans gewährt und vom Vergütungsausschuss genehmigt. Der Vesting-Zeitplan sieht vor, dass ein Drittel der Aktien an jedem der ersten drei Jahrestage der Gewährung fällig wird, vorausgesetzt, der Dienst wird kontinuierlich fortgesetzt. Die Optionen verfallen nach zehn Jahren und wurden als wesentlicher Anreiz für die Beschäftigung gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
- None.
- None.
BEDFORD, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the Osteoarthritis (“OA”) Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced that on April 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of
Of the shares covered by the Options, one-third will vest on each of the first three anniversaries of the grant date, in each case for so long as the grantee provides continuous service to Anika through the relevant vesting date.
Unless earlier terminated in accordance with their terms, the Options will expire on the tenth anniversary of the grant date and are otherwise subject to the terms and conditions of the equity award agreement approved by Anika. The Options were granted pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, which was not subject to stockholder approval.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Leveraging our core expertise in hyaluronic acid and implant solutions, we partner with clinicians to provide minimally invasive products that restore active living for people around the world. Our focus is on high opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, and our products are efficiently delivered in key sites of care, including ambulatory surgery centers. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Director, Corporate Development and Investor Relations
investorrelations@anika.com
FAQ
What are the terms of ANIK's April 2025 stock option grant?
How does the vesting schedule work for ANIK's April 2025 inducement grant?
What is the exercise price for ANIK's April 2025 inducement stock options?
When do the ANIK April 2025 inducement stock options expire?
